开发和验证一个模型来预测阿尔茨海默病的进展
Chenyin Chu1, Yihan Wang1, Andrew L H Huynh2
1Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
Age and ageing
|July 24, 2025
概括
一个新的机器学习模型,弗洛里融合模型 (FFM),显示了对监测轻度认知障碍 (MCI) 和阿尔茨海默氏症痴呆症 (AD) 患者认知衰退的希望. FFM准确地预测了这些神经退行性疾病的进展,并有助于对这些神经退行性疾病的护理计划.
科学领域:
- 神经科学和人工智能 人工智能
- 生物医学信息学 生物医学信息学
- 老年学是指老年学的学科.
背景情况:
- 认知监测对于轻度认知障碍 (MCI) 和阿尔茨海默氏症痴呆症 (AD) 患者的有效护理规划至关重要.
- 认知衰退的准确预测有助于及时干预和管理策略.
研究的目的:
- 开发和验证一种机器学习模型,即弗洛里融合模型 (FFM),用于协助对认知功能的监测.
- 评估FFM对轻度认知障碍 (MCI) 到阿尔茨海默氏症痴呆症 (AD) 进展的预测准确度.
主要方法:
- 弗洛里融合模型 (FFM) 是使用机器学习算法 (支持向量机器,梯度增强,随机森林) 在澳大利亚成像,生物标志物和衰老生活方式 (AIBL) 研究的数据上开发的.
- 模型验证包括两个阶段:对238名参与者的交叉验证和对30名额外参与者的模拟/缺失数据试验.
- 认知能力下降的评估是使用临床痴呆症评分盒总和 (CDR-SB) 和迷你精神状态检查 (MMSE) 分数进行的.
主要成果:
- 在预测MCI-to-AD进展方面,FFM表现出强的表现,接收器操作特征曲线 (AUC-ROC) 下的中间面积为0.91.
- 对于三年认知预测,该模型的平均绝对误差 (MAE) 为CDR-SB的1.32和MMSE的1.51.
- 模拟和缺失数据试验显示,MCI转换为AD的准确率高达94%,CDR-SB得分预测的MAE为1.27-2.12.
结论:
- 弗洛里融合模型 (FFM) 显示了增强MCI和AD患者认知监测的巨大潜力.
- 通过更大的临床试验进行进一步的验证是必要的,以确定FFM作为广泛使用的临床级工具.
更多相关视频
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.5K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.3K
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
